Continuous treatment of these cell lines with ruxolitinib decreases both the efficiency of colony formation (Fig. 6A) and the average size of colonies (Fig. 6B) in three of the four lines, indicating that JAK2/STAT3 signaling is important for anchorage-independent growth of specific subsets of NSCLC. Here, STAT3 is linked to non-small cell lung carcinoma.